Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the ...
activity for increased therapeutic efficacy. The platform removes the core fucose from Fc N-glycans through knockout of the host (FUT8) gene to achieve higher ADCC activity while retaining desired ...
It did not have a significantly different therapeutic efficacy from the commercial paste dosage form in the treatment of oral lichen planus. Buffering agents and an antioxidant should be added to ...
SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...